{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:55:54Z","timestamp":1790596554015,"version":"4.1.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P50CA058236, R01CA183965, R01CA070196, P30CA006973, S10RR026824, UL1TR003098"],"award-info":[{"award-number":["P50CA058236, R01CA183965, R01CA070196, P30CA006973, S10RR026824, UL1TR003098"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["Challenge Awards"],"award-info":[{"award-number":["Challenge Awards"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-76852-2","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:14:41Z","timestamp":1787768081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Triptolide sensitizes cancer cells to nucleoside DNA methyltransferase inhibitors through inhibition of DCTPP1-mediated cell-intrinsic resistance"],"prefix":"10.1038","volume":"17","author":[{"given":"Jianyong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Li","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianya","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay M.","family":"Vaghasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7784-6085","authenticated-orcid":false,"given":"Roshan","family":"Chikarmane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Hauk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Rachakonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2897-7561","authenticated-orcid":false,"given":"Ruchama C.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh-Tam","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2024-8586","authenticated-orcid":false,"given":"Jordan M.","family":"Gregg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0722-7407","authenticated-orcid":false,"given":"Yuhan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2766-5817","authenticated-orcid":false,"given":"Jasmine Yun-Tong","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresia M.","family":"Wanjiku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Nuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0167-7307","authenticated-orcid":false,"given":"Joong Sup","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Giovinazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Esopi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunhwa","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Coulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6177-1058","authenticated-orcid":false,"given":"Rulin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Rudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Gabrielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4847-5307","authenticated-orcid":false,"given":"Angelo M.","family":"De Marzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0666-1240","authenticated-orcid":false,"given":"James M.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3842-9841","authenticated-orcid":false,"given":"Jun O.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4379-0730","authenticated-orcid":false,"given":"William G.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0744-6606","authenticated-orcid":false,"given":"Srinivasan","family":"Yegnasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"76852_CR1","first-page":"531","volume":"7","author":"JD Brooks","year":"1998","unstructured":"Brooks, J. D. et al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol. Biomark. Prev. 7, 531\u2013536 (1998).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"76852_CR2","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"JG Herman","year":"2003","unstructured":"Herman, J. G. & Baylin, S. B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042\u20132054 (2003).","journal-title":"N. Engl. J. Med."},{"key":"76852_CR3","first-page":"8611","volume":"61","author":"X Lin","year":"2001","unstructured":"Lin, X. et al. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res. 61, 8611\u20138616 (2001).","journal-title":"Cancer Res."},{"key":"76852_CR4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0002-9440(10)63452-9","volume":"163","author":"M Nakayama","year":"2003","unstructured":"Nakayama, M. et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am. J. Pathol. 163, 923\u2013933 (2003).","journal-title":"Am. J. Pathol."},{"key":"76852_CR5","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1158\/0008-5472.CAN-03-3972","volume":"64","author":"S Yegnasubramanian","year":"2004","unstructured":"Yegnasubramanian, S. et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 64, 1975\u20131986 (2004).","journal-title":"Cancer Res."},{"key":"76852_CR6","doi-asserted-by":"publisher","first-page":"11995","DOI":"10.1073\/pnas.90.24.11995","volume":"90","author":"F Antequera","year":"1993","unstructured":"Antequera, F. & Bird, A. Number of CpG islands and genes in human and mouse. Proc. Natl. Acad. Sci. USA 90, 11995\u201311999 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76852_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/321209a0","volume":"321","author":"AP Bird","year":"1986","unstructured":"Bird, A. P. CpG-rich islands and the function of DNA methylation. Nature 321, 209\u2013213 (1986).","journal-title":"Nature"},{"key":"76852_CR8","doi-asserted-by":"publisher","first-page":"169ra110","DOI":"10.1126\/scitranslmed.3005211","volume":"5","author":"MJ Aryee","year":"2013","unstructured":"Aryee, M. J. et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci. Transl. Med. 5, 169ra110 (2013).","journal-title":"Sci. Transl. Med."},{"key":"76852_CR9","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli, K. B. et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162, 974\u2013986 (2015).","journal-title":"Cell"},{"key":"76852_CR10","doi-asserted-by":"publisher","first-page":"8954","DOI":"10.1158\/0008-5472.CAN-07-6088","volume":"68","author":"S Yegnasubramanian","year":"2008","unstructured":"Yegnasubramanian, S. et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 68, 8954\u20138967 (2008).","journal-title":"Cancer Res."},{"key":"76852_CR11","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1128\/MCB.25.11.4727-4741.2005","volume":"25","author":"K Ghoshal","year":"2005","unstructured":"Ghoshal, K. et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol. Cell Biol. 25, 4727\u20134741 (2005).","journal-title":"Mol. Cell Biol."},{"key":"76852_CR12","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1093\/nar\/gkq187","volume":"38","author":"K Patel","year":"2010","unstructured":"Patel, K. et al. Targeting of 5-aza-2\u2019-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res. 38, 4313\u20134324 (2010).","journal-title":"Nucleic Acids Res."},{"key":"76852_CR13","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.tips.2010.08.001","volume":"31","author":"X Yang","year":"2010","unstructured":"Yang, X., Lay, F., Han, H. & Jones, P. A. Targeting DNA methylation for epigenetic therapy. Trends Pharm. Sci. 31, 536\u2013546 (2010).","journal-title":"Trends Pharm. Sci."},{"key":"76852_CR14","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1200\/JCO.2006.09.4169","volume":"25","author":"W Blum","year":"2007","unstructured":"Blum, W. et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J. Clin. Oncol. 25, 3884\u20133891 (2007).","journal-title":"J. Clin. Oncol."},{"key":"76852_CR15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","volume":"28","author":"AF Cashen","year":"2010","unstructured":"Cashen, A. F., Schiller, G. J., O\u2019Donnell, M. R. & DiPersio, J. F. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J. Clin. Oncol. 28, 556\u2013561 (2010).","journal-title":"J. Clin. Oncol."},{"key":"76852_CR16","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","volume":"103","author":"JP Issa","year":"2004","unstructured":"Issa, J. P. et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2\u2019-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103, 1635\u20131640 (2004).","journal-title":"Blood"},{"key":"76852_CR17","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian, H. et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106, 1794\u20131803 (2006).","journal-title":"Cancer"},{"key":"76852_CR18","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1038\/ncponc0347","volume":"2","author":"LR Silverman","year":"2005","unstructured":"Silverman, L. R. & Mufti, G. J. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat. Clin. Pr. Oncol. 2, S12\u2013S23 (2005).","journal-title":"Nat. Clin. Pr. Oncol."},{"key":"76852_CR19","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1111\/bph.12885","volume":"172","author":"D Cheishvili","year":"2015","unstructured":"Cheishvili, D., Boureau, L. & Szyf, M. DNA demethylation and invasive cancer: implications for therapeutics. Br. J. Pharm. 172, 2705\u20132715 (2015).","journal-title":"Br. J. Pharm."},{"key":"76852_CR20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrg816","volume":"3","author":"PA Jones","year":"2002","unstructured":"Jones, P. A. & Baylin, S. B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3, 415\u2013428 (2002).","journal-title":"Nat. Rev. Genet."},{"key":"76852_CR21","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S0026-895X(24)09243-5","volume":"59","author":"AR Karpf","year":"2001","unstructured":"Karpf, A. R., Moore, B. C., Ririe, T. O. & Jones, D. A. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2\u2019-deoxycytidine. Mol. Pharm. 59, 751\u2013757 (2001).","journal-title":"Mol. Pharm."},{"key":"76852_CR22","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1128\/MCB.01799-07","volume":"28","author":"SS Palii","year":"2008","unstructured":"Palii, S. S., Van Emburgh, B. O., Sankpal, U. T., Brown, K. D. & Robertson, K. D. DNA methylation inhibitor 5-Aza-2\u2019-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol. Cell Biol. 28, 752\u2013771 (2008).","journal-title":"Mol. Cell Biol."},{"key":"76852_CR23","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1158\/1078-0432.CCR-08-2783","volume":"15","author":"JP Issa","year":"2009","unstructured":"Issa, J. P. & Kantarjian, H. M. Targeting DNA methylation. Clin. Cancer Res. 15, 3938\u20133946 (2009).","journal-title":"Clin. Cancer Res."},{"key":"76852_CR24","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.18632\/oncotarget.597","volume":"3","author":"Q Ebrahem","year":"2012","unstructured":"Ebrahem, Q., Mahfouz, R. Z., Ng, K. P. & Saunthararajah, Y. High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. Oncotarget 3, 1137\u20131145 (2012).","journal-title":"Oncotarget"},{"key":"76852_CR25","doi-asserted-by":"publisher","first-page":"e23372","DOI":"10.1371\/journal.pone.0023372","volume":"6","author":"T Qin","year":"2011","unstructured":"Qin, T. et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS ONE 6, e23372 (2011).","journal-title":"PLoS ONE"},{"key":"76852_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nature14948","volume":"524","author":"M Zauri","year":"2015","unstructured":"Zauri, M. et al. CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer. Nature 524, 114\u2013118 (2015).","journal-title":"Nature"},{"key":"76852_CR27","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1182\/blood-2011-08-371690","volume":"119","author":"D Lavelle","year":"2012","unstructured":"Lavelle, D. et al. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood 119, 1240\u20131247 (2012).","journal-title":"Blood"},{"key":"76852_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00280-008-0750-6","volume":"63","author":"M Lemaire","year":"2009","unstructured":"Lemaire, M., Momparler, L. F., Raynal, N. J., Bernstein, M. L. & Momparler, R. L. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2\u2019-deoxycytidine. Cancer Chemother. Pharm. 63, 411\u2013416 (2009).","journal-title":"Cancer Chemother. Pharm."},{"key":"76852_CR29","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1470-2045(15)00038-8","volume":"16","author":"JP Issa","year":"2015","unstructured":"Issa, J. P. et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 16, 1099\u20131110 (2015).","journal-title":"Lancet Oncol."},{"key":"76852_CR30","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1182\/blood.2019004143","volume":"136","author":"G Garcia-Manero","year":"2020","unstructured":"Garcia-Manero, G. et al. Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study. Blood 136, 674\u2013683 (2020).","journal-title":"Blood"},{"key":"76852_CR31","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/S2352-3026(19)30030-4","volume":"6","author":"MR Savona","year":"2019","unstructured":"Savona, M. R. et al. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 6, e194\u2013e203 (2019).","journal-title":"Lancet Haematol."},{"key":"76852_CR32","doi-asserted-by":"publisher","first-page":"e2445","DOI":"10.1371\/journal.pone.0002445","volume":"3","author":"G Chai","year":"2008","unstructured":"Chai, G. et al. HDAC inhibitors act with 5-aza-2\u2019-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. PLoS ONE 3, e2445 (2008).","journal-title":"PLoS ONE"},{"key":"76852_CR33","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.1182\/blood-2011-02-336891","volume":"118","author":"M Kalac","year":"2011","unstructured":"Kalac, M. et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood 118, 5506\u20135516 (2011).","journal-title":"Blood"},{"key":"76852_CR34","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1158\/1535-7163.MCT-10-0309","volume":"9","author":"W Luszczek","year":"2010","unstructured":"Luszczek, W., Cheriyath, V., Mekhail, T. M. & Borden, E. C. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression. Mol. Cancer Ther. 9, 2309\u20132321 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"76852_CR35","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nchembio806","volume":"2","author":"CR Chong","year":"2006","unstructured":"Chong, C. R., Chen, X., Shi, L., Liu, J. O. & Sullivan, D. J. Jr A clinical drug library screen identifies astemizole as an antimalarial agent. Nat. Chem. Biol. 2, 415\u2013416 (2006).","journal-title":"Nat. Chem. Biol."},{"key":"76852_CR36","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8274.CD-10-0020","volume":"1","author":"EA Platz","year":"2011","unstructured":"Platz, E. A. et al. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov. 1, 68\u201377 (2011).","journal-title":"Cancer Discov."},{"key":"76852_CR37","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1158\/1078-0432.CCR-12-2127","volume":"19","author":"H Kamiyama","year":"2013","unstructured":"Kamiyama, H. et al. Personalized chemotherapy profiling using cancer cell lines from selectable mice. Clin. Cancer Res. 19, 1139\u20131146 (2013).","journal-title":"Clin. Cancer Res."},{"key":"76852_CR38","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440\u2013446 (2010).","journal-title":"Cancer Res."},{"key":"76852_CR39","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccr.2012.02.028","volume":"21","author":"G Wei","year":"2012","unstructured":"Wei, G. et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell 21, 547\u2013562 (2012).","journal-title":"Cancer Cell"},{"key":"76852_CR40","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nchembio.522","volume":"7","author":"DV Titov","year":"2011","unstructured":"Titov, D. V. et al. XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat. Chem. Biol. 7, 182\u2013188 (2011).","journal-title":"Nat. Chem. Biol."},{"key":"76852_CR41","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1039\/c2np00088a","volume":"29","author":"ZL Zhou","year":"2012","unstructured":"Zhou, Z. L., Yang, Y. X., Ding, J., Li, Y. C. & Miao, Z. H. Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms. Nat. Prod. Rep. 29, 457\u2013475 (2012).","journal-title":"Nat. Prod. Rep."},{"key":"76852_CR42","doi-asserted-by":"publisher","first-page":"156ra139","DOI":"10.1126\/scitranslmed.3004334","volume":"4","author":"R Chugh","year":"2012","unstructured":"Chugh, R. et al. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci. Transl. Med. 4, 156ra139 (2012).","journal-title":"Sci. Transl. Med."},{"key":"76852_CR43","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/cbic.201100007","volume":"12","author":"TW Corson","year":"2011","unstructured":"Corson, T. W., Cavga, H., Aberle, N. & Crews, C. M. Triptolide directly inhibits dCTP pyrophosphatase. Chembiochem. 12, 1767\u20131773 (2011).","journal-title":"Chembiochem"},{"key":"76852_CR44","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/anie.201408817","volume":"54","author":"QL He","year":"2015","unstructured":"He, Q. L. et al. Covalent modification of a cysteine residue in the XPB subunit of the general transcription factor TFIIH through single epoxide cleavage of the transcription inhibitor triptolide. Angew. Chem. Int. Ed. Engl. 54, 1859\u20131863 (2015).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"76852_CR45","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1073\/pnas.0700499104","volume":"104","author":"SJ Leuenroth","year":"2007","unstructured":"Leuenroth, S. J. et al. Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc. Natl. Acad. Sci. USA. 104, 4389\u20134394 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76852_CR46","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.chembiol.2013.12.009","volume":"21","author":"Y Lu","year":"2014","unstructured":"Lu, Y. et al. TAB1: a target of triptolide in macrophages. Chem. Biol. 21, 246\u2013256 (2014).","journal-title":"Chem. Biol."},{"key":"76852_CR47","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.4161\/cbt.8.21.9803","volume":"8","author":"R Soundararajan","year":"2009","unstructured":"Soundararajan, R., Sayat, R., Robertson, G. S. & Marignani, P. A. Triptolide: an inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells. Cancer Biol. Ther. 8, 2054\u20132062 (2009).","journal-title":"Cancer Biol. Ther."},{"key":"76852_CR48","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nchembio.1550","volume":"10","author":"Y Smurnyy","year":"2014","unstructured":"Smurnyy, Y. et al. DNA sequencing and CRISPR-Cas9 gene editing for target validation in mammalian cells. Nat. Chem. Biol. 10, 623\u2013625 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"76852_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2015.10","volume":"4","author":"FF Song","year":"2015","unstructured":"Song, F. F. et al. Human dCTP pyrophosphatase 1 promotes breast cancer cell growth and stemness through the modulation on 5-methyl-dCTP metabolism and global hypomethylation. Oncogenesis 4, e159 (2015).","journal-title":"Oncogenesis"},{"key":"76852_CR50","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1042\/BJ20130894","volume":"459","author":"CE Requena","year":"2014","unstructured":"Requena, C. E., Perez-Moreno, G., Ruiz-Perez, L. M., Vidal, A. E. & Gonzalez-Pacanowska, D. The NTP pyrophosphatase DCTPP1 contributes to the homoeostasis and cleansing of the dNTP pool in human cells. Biochem. J. 459, 171\u2013180 (2014).","journal-title":"Biochem. J."},{"key":"76852_CR51","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.jmb.2007.01.057","volume":"367","author":"B Wu","year":"2007","unstructured":"Wu, B. et al. Crystal structure of RS21-C6, involved in nucleoside triphosphate pyrophosphohydrolysis. J. Mol. Biol. 367, 1405\u20131412 (2007).","journal-title":"J. Mol. Biol."},{"key":"76852_CR52","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.jmb.2020.01.005","volume":"432","author":"E Scaletti","year":"2020","unstructured":"Scaletti, E., Claesson, M., Helleday, T., Jemth, A. S. & Stenmark, P. The first structure of an active mammalian dCTPase and its complexes with substrate analogs and products. J. Mol. Biol. 432, 1126\u20131142 (2020).","journal-title":"J. Mol. Biol."},{"key":"76852_CR53","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jchromb.2016.03.029","volume":"1022","author":"NM Anders","year":"2016","unstructured":"Anders, N. M. et al. Simultaneous quantitative determination of 5-aza-2\u2019-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1022, 38\u201345 (2016).","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"76852_CR54","doi-asserted-by":"publisher","first-page":"e75258","DOI":"10.1371\/journal.pone.0075258","volume":"8","author":"N Blagitko-Dorfs","year":"2013","unstructured":"Blagitko-Dorfs, N. et al. Epigenetic priming of AML blasts for all-trans retinoic acid-induced differentiation by the HDAC class-I selective inhibitor entinostat. PLoS ONE 8, e75258 (2013).","journal-title":"PLoS ONE"},{"key":"76852_CR55","doi-asserted-by":"publisher","first-page":"e87475","DOI":"10.1371\/journal.pone.0087475","volume":"9","author":"SM Leonard","year":"2014","unstructured":"Leonard, S. M., Perry, T., Woodman, C. B. & Kearns, P. Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia. PLoS ONE 9, e87475 (2014).","journal-title":"PLoS ONE"},{"key":"76852_CR56","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1182\/blood-2010-11-320093","volume":"118","author":"JM Scandura","year":"2011","unstructured":"Scandura, J. M. et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood 118, 1472\u20131480 (2011).","journal-title":"Blood"},{"key":"76852_CR57","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.ccr.2011.12.029","volume":"21","author":"HC Tsai","year":"2012","unstructured":"Tsai, H. C. et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21, 430\u2013446 (2012).","journal-title":"Cancer Cell"},{"key":"76852_CR58","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.3109\/10428194.2015.1091931","volume":"57","author":"XN Ye","year":"2016","unstructured":"Ye, X. N. et al. Epigenetic priming with decitabine followed by low-dose idarubicin\/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms. Leuk. Lymphoma 57, 1311\u20131318 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"76852_CR59","first-page":"48","volume":"57","author":"JM Barletta","year":"1997","unstructured":"Barletta, J. M., Rainier, S. & Feinberg, A. P. Reversal of loss of imprinting in tumor cells by 5-aza-2\u2019-deoxycytidine. Cancer Res. 57, 48\u201350 (1997).","journal-title":"Cancer Res."},{"key":"76852_CR60","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1093\/nar\/gkt240","volume":"41","author":"Y Ito","year":"2013","unstructured":"Ito, Y., Nativio, R. & Murrell, A. Induced DNA demethylation can reshape chromatin topology at the IGF2-H19 locus. Nucleic Acids Res. 41, 5290\u20135302 (2013).","journal-title":"Nucleic Acids Res."},{"key":"76852_CR61","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois, D. et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961\u2013973 (2015).","journal-title":"Cell"},{"key":"76852_CR62","doi-asserted-by":"publisher","first-page":"D1023","DOI":"10.1093\/nar\/gkv1268","volume":"44","author":"M Zhao","year":"2016","unstructured":"Zhao, M., Kim, P., Mitra, R., Zhao, J. & Zhao, Z. TSGene 2.0: an updated literature-based knowledgebase for tumor suppressor genes. Nucleic Acids Res. 44, D1023\u2013D1031 (2016).","journal-title":"Nucleic Acids Res."},{"key":"76852_CR63","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41420-025-02666-8","volume":"11","author":"Y Lu","year":"2025","unstructured":"Lu, Y. et al. DCTPP1 regulates oxidative stress homeostasis via AUF1 in human villous trophoblasts. Cell Death Discov. 11, 400 (2025).","journal-title":"Cell Death Discov."},{"key":"76852_CR64","doi-asserted-by":"publisher","first-page":"104348","DOI":"10.1016\/j.drudis.2025.104348","volume":"30","author":"S Liu","year":"2025","unstructured":"Liu, S., Feng, L. & Wang, Z. DCTPP1: a promising target in cancer therapy and prognosis through nucleotide metabolism. Drug Discov. Today 30, 104348 (2025).","journal-title":"Drug Discov. Today"},{"key":"76852_CR65","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"76852_CR66","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 6, pl1 (2013).","journal-title":"Sci. Signal"},{"key":"76852_CR67","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617\u2013629 (2020).","journal-title":"N. Engl. J. Med."},{"key":"76852_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00770-x","volume":"12","author":"D Kwag","year":"2022","unstructured":"Kwag, D. et al. Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis. Blood Cancer J. 12, 169 (2022).","journal-title":"Blood Cancer J."},{"key":"76852_CR69","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1038\/ncponc0354","volume":"2","author":"SB Baylin","year":"2005","unstructured":"Baylin, S. B. DNA methylation and gene silencing in cancer. Nat. Clin. Pr. Oncol. 2, S4\u2013S11 (2005).","journal-title":"Nat. Clin. Pr. Oncol."},{"key":"76852_CR70","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1158\/1535-7163.MCT-07-0010","volume":"6","author":"T Kiziltepe","year":"2007","unstructured":"Kiziltepe, T. et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol. Cancer Ther. 6, 1718\u20131727 (2007).","journal-title":"Mol. Cancer Ther."},{"key":"76852_CR71","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1042\/BCJ20160302","volume":"473","author":"CE Requena","year":"2016","unstructured":"Requena, C. E. et al. The nucleotidohydrolases DCTPP1 and dUTPase are involved in the cellular response to decitabine. Biochem. J. 473, 2635\u20132643 (2016).","journal-title":"Biochem. J."},{"key":"76852_CR72","doi-asserted-by":"publisher","DOI":"10.4081\/ejh.2013.e29","volume":"57","author":"Y Zhang","year":"2013","unstructured":"Zhang, Y. et al. dCTP pyrophosphohydrase exhibits nucleic accumulation in multiple carcinomas. Eur. J. Histochem. 57, e29 (2013).","journal-title":"Eur. J. Histochem."},{"key":"76852_CR73","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1158\/1078-0432.CCR-12-1722","volume":"19","author":"RZ Mahfouz","year":"2013","unstructured":"Mahfouz, R. Z. et al. Increased CDA expression\/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin. Cancer Res. 19, 938\u2013948 (2013).","journal-title":"Clin. Cancer Res."},{"key":"76852_CR74","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ijc.23607","volume":"123","author":"C Stresemann","year":"2008","unstructured":"Stresemann, C. & Lyko, F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer 123, 8\u201313 (2008).","journal-title":"Int. J. Cancer"},{"key":"76852_CR75","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.leukres.2014.08.016","volume":"39","author":"P Wu","year":"2015","unstructured":"Wu, P. et al. The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome. Leuk. Res. 39, 216\u2013220 (2015).","journal-title":"Leuk. Res."},{"key":"76852_CR76","first-page":"371","volume":"1","author":"JR Kroep","year":"2002","unstructured":"Kroep, J. R. et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol. Cancer Ther. 1, 371\u2013376 (2002).","journal-title":"Mol. Cancer Ther."},{"key":"76852_CR77","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.chembiol.2023.07.017","volume":"30","author":"TP Nguyen","year":"2023","unstructured":"Nguyen, T. P. et al. Inducible mismatch repair streamlines forward genetic approaches to target identification of cytotoxic small molecules. Cell Chem. Biol. 30, 1453\u20131467 e1458 (2023).","journal-title":"Cell Chem. Biol."},{"key":"76852_CR78","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature13181","volume":"508","author":"H Gad","year":"2014","unstructured":"Gad, H. et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature 508, 215\u2013221 (2014).","journal-title":"Nature"},{"key":"76852_CR79","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1021\/acs.jmedchem.5b01741","volume":"59","author":"S Llona-Minguez","year":"2016","unstructured":"Llona-Minguez, S. et al. Discovery of the first potent and selective inhibitors of human dCTP pyrophosphatase 1. J. Med. Chem. 59, 1140\u20131148 (2016).","journal-title":"J. Med. Chem."},{"key":"76852_CR80","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1016\/j.bmcl.2017.06.039","volume":"27","author":"S Llona-Minguez","year":"2017","unstructured":"Llona-Minguez, S. et al. Diverse heterocyclic scaffolds as dCTP pyrophosphatase 1 inhibitors. Part 2: pyridone- and pyrimidinone-derived systems. Bioorg. Med. Chem. Lett. 27, 3219\u20133225 (2017).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"76852_CR81","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1016\/j.bmcl.2017.06.038","volume":"27","author":"S Llona-Minguez","year":"2017","unstructured":"Llona-Minguez, S. et al. Diverse heterocyclic scaffolds as dCTP pyrophosphatase 1 inhibitors. Part 1: triazoles, triazolopyrimidines, triazinoindoles, quinoline hydrazones and arylpiperazines. Bioorg. Med. Chem. Lett. 27, 3897\u20133904 (2017).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"76852_CR82","doi-asserted-by":"publisher","first-page":"e187490","DOI":"10.1172\/JCI187490","volume":"135","author":"Z Duan","year":"2025","unstructured":"Duan, Z. et al. PROX1 is an early driver of lineage plasticity in prostate cancer. J. Clin. Invest. 135, e187490 (2025).","journal-title":"J. Clin. Invest."},{"key":"76852_CR83","doi-asserted-by":"publisher","first-page":"e146827","DOI":"10.1172\/jci.insight.146827","volume":"6","author":"WN Brennen","year":"2021","unstructured":"Brennen, W. N. et al. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. JCI Insight 6, e146827 (2021).","journal-title":"JCI Insight"},{"key":"76852_CR84","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf6732","volume":"15","author":"Y Yamada","year":"2023","unstructured":"Yamada, Y. et al. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer. Sci. Transl. Med. 15, eadf6732 (2023).","journal-title":"Sci. Transl. Med."},{"key":"76852_CR85","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1158\/0008-5472.CAN-25-0636","volume":"85","author":"VB Venkadakrishnan","year":"2025","unstructured":"Venkadakrishnan, V. B. et al. Epigenetic derepression of PROX1 promotes neuroendocrine prostate cancer progression. Cancer Res. 85, 3842\u20133854 (2025).","journal-title":"Cancer Res."},{"key":"76852_CR86","doi-asserted-by":"publisher","first-page":"e185952","DOI":"10.1172\/jci.insight.185952","volume":"9","author":"S Nouruzi","year":"2024","unstructured":"Nouruzi, S. et al. ASCL1 regulates and cooperates with FOXA2 to drive terminal neuroendocrine phenotype in prostate cancer. JCI Insight 9, e185952 (2024).","journal-title":"JCI Insight"},{"key":"76852_CR87","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.ccell.2025.03.027","volume":"43","author":"M Teng","year":"2025","unstructured":"Teng, M. et al. Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation. Cancer Cell 43, 891\u2013904 e810 (2025).","journal-title":"Cancer Cell"},{"key":"76852_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23780-y","volume":"12","author":"NJ Brady","year":"2021","unstructured":"Brady, N. J. et al. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nat. Commun. 12, 3372 (2021).","journal-title":"Nat. Commun."},{"key":"76852_CR89","doi-asserted-by":"crossref","unstructured":"Singh, R. et al. Crosstalk between EZH2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity. Nat. Commun. 17, 2992 (2026).","DOI":"10.1038\/s41467-026-69308-0"},{"key":"76852_CR90","doi-asserted-by":"publisher","first-page":"e92444","DOI":"10.1371\/journal.pone.0092444","volume":"9","author":"C Guzman","year":"2014","unstructured":"Guzman, C., Bagga, M., Kaur, A., Westermarck, J. & Abankwa, D. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS ONE 9, e92444 (2014).","journal-title":"PLoS ONE"},{"key":"76852_CR91","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1093\/nar\/18.20.6069","volume":"18","author":"C Aslanidis","year":"1990","unstructured":"Aslanidis, C. & de Jong, P. J. Ligation-independent cloning of PCR products (LIC-PCR). Nucleic Acids Res. 18, 6069\u20136074 (1990).","journal-title":"Nucleic Acids Res."},{"key":"76852_CR92","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ymeth.2011.06.010","volume":"55","author":"G Winter","year":"2011","unstructured":"Winter, G. & McAuley, K. E. Automated data collection for macromolecular crystallography. Methods 55, 81\u201393 (2011).","journal-title":"Methods"},{"key":"76852_CR93","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"76852_CR94","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"76852_CR95","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"76852_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"76852_CR97","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76852_CR98","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"76852_CR99","unstructured":"Wickham, H. ggplot2 : Elegant Graphics for Data Analysisin. 2nd edition, 1 online resource. (Springer International Publishing, Imprint, Springer, Cham, 2016)."},{"key":"76852_CR100","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"76852_CR101","doi-asserted-by":"publisher","unstructured":"Korotkevich, G. et al. Fast gene set enrichment analysis. biorxiv. https:\/\/doi.org\/10.1101\/060012 (2021).","DOI":"10.1101\/060012"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76852-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76852-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76852-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:04:15Z","timestamp":1790593455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76852-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76852"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76852-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.L., J.O.L., W.G.N., and S.Y. are inventors on a provisional patent related to this work.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10240"}}